9. January 2015

FDA Approves Roche's Blood Screening Assay for Simultaneous Detection and Identification of Three Major Viral Targets

Roche announced today that the FDA has approved the cobasĀ® TaqScreen MPX Test, v2.0 for use in the detection and identification of HIV, HCV, and HBV in donations of human whole blood and blood components including source plasma.


Learn about the role of HPV in cervical cancer
What's New

13. August 2015

Roche acquires GeneWEAVE to strengthen offerings in microbiology diagnostics

Roche today announced that it has signed a definitive agreement to acquire GeneWEAVE BioSciences, Inc., a privately held company focused on innovative, clinical microbiology diagnostics solutions based in Los Gatos, CA, USA.


30. July 2015

Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy

The cobasĀ® EGFR Mutation Test v2 is designed for expanded EGFR mutation detection in non-small cell lung cancer patients.


19. July 2015

Roche expands HIV Global Access Program to include infants in resource limited settings

Program adds early infant testing to further support the 90:90:90 UNAIDS goal.


18. June 2015

Roche to provide HIV diagnostic solutions to Global Fund

Framework agreement with Global Fund strengthens access to HIV diagnostics.


 Diagnostic and Blood Screening Tests


Roche Molecular Diagnostics (RMD) offers a uniquely broad range of diagnostic and blood screening assays based on the company's Nobel prize-winning PCR technologies.


RMD's tests and automated platforms are focused in the areas of virology, blood screening, HPV, genomics and oncology, microbiology and sexually transmitted infections. > more


Contact your local sales representative for detailed information, questions and ordering.



 Browse Our Products

 Related Links